Patient disposition, duration of treatment, and ruxolitinib exposure. (A) Study flowchart. The 7 adverse events, regardless of treatment, that led to discontinuation were severe blood creatine phosphokinase increase, severe gastrointestinal disorder, Kaposi sarcoma, moderate left-foot pain, severe multiorgan failure, moderate renal failure, and mild right-foot pain (n = 1 each). Consent was withdrawn because of concern over weight gain, concern over fatigue, and planning a pregnancy (n = 1 each). Death was due to progressive heart failure in 1 patient and multiple vertebral osteolytic lesions due to Paget’s disease in the other patient. (B) Duration of treatment in individual patients. (C) Ruxolitinib daily dosage distribution over time: patients from all ruxolitinib starting dose groups were included and analyzed by ruxolitinib average total daily dose.